NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: HESTERBIO · data 2026-10-31
Hester Biosciences Limited
In plain words
Price: 14.7% below its 52-week high of ₹2,683.6.
Delivery: 53.8% of traded shares were kept for delivery over the last 10 sessions, against 51.1% over the last 60.
Latest results: a net profit of ₹14 cr for the quarter ended Sept 2025.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹326 cr |
| Net profit (last 12 months) | ₹136 cr |
| Sales growth, 3 years (yearly) | 7.7% |
| Profit growth, 3 years (yearly) | 27.8% |
At a glance
Promoters 53.7%, pledged 0.0%, institutions 0.3%.
P/E 14.3, dividend yield 0.5%. Price relative to earnings and book value (low is cheaper, not better).
ROE 16.5%, ROCE 13.0%, operating margin 19.9%: how much profit it earns on the money it uses.
Debt/equity 0.54, Profit growth 27.8% and sales growth 7.7% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 27.8% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY26)
Quarter: Q2 FY26
Revenue: Rs 70.97 crore
Net profit: Rs 14.45 crore
Operating margin: 16.5%
EPS: Rs 16.85
त्रैमासिक: Q2 FY26
राजस्व: Rs 70.97 करोड़
शुद्ध लाभ: Rs 14.45 करोड़
ऑपरेटिंग मार्जिन: 16.5%
प्रति शेयर आय: Rs 16.85
ત્રિમાસિક: Q2 FY26
રેવન્યુ: Rs 70.97 કરોડ
નેટ પ્રોફિટ: Rs 14.45 કરોડ
ઓપરેટિંગ માર્જિન: 16.5%
EPS: Rs 16.85
Written by AI from the filed numbers and checked against them. Not a recommendation.
Earnings call in brief (1 Aug 2026)
- Management said that on a standalone basis, revenue from operations grew by 14% and PAT increased by 88% over the corresponding quarter of the previous year, while gross margins improved from 69% to 78% supported by a favorable product mix and operational efficiencies, and EBITDA grew by 95%.
- Management said that at a consolidated level, revenue from operations declined by 8% mainly due to lower revenues from Nepal and Africa operations, and consolidated profitability includes an exceptional accounting gain from the amendment of the soft loan extended to Hester Africa by the Gates Foundation, where the loan was reduced from USD 12 million to USD 5 million, accrued interest was waived, and the revised loan was made interest-free.
- Management said that the Poultry Healthcare Division grew by 48% over the corresponding year quarter, supported by higher institutional business, deeper market penetration, customer engagement, and early traction in feed supplements and disinfectant solutions.
- Management said that the Animal Healthcare Division was impacted by the timing of government-led immunization programs like PPR eradication and the Lumpy Skin Disease Control Initiative for Goat Pox supply, which they maintain is a timing-related issue rather than an underlying demand problem.
- Management said that regulatory dossiers in the animal health segment were submitted during the quarter to expand the biological pipeline, and the consolidated debt as on 30th June stood at Rs. 103 crores.
- प्रबंधन ने कहा कि स्टैंडअलोन आधार पर, परिचालन से राजस्व में पिछले वर्ष की इसी तिमाही की तुलना में 14% की वृद्धि हुई और PAT में 88% की वृद्धि हुई, जबकि अनुकूल उत्पाद मिश्रण और परिचालन दक्षता के कारण सकल मार्जिन 69% से सुधरकर 78% हो गया, और EBITDA में 95% की वृद्धि हुई।
- प्रबंधन ने कहा कि समेकित स्तर पर, नेपाल और अफ्रीका के परिचालन से कम राजस्व के कारण परिचालन से राजस्व में 8% की गिरावट आई, और समेकित लाभप्रदता में गेट्स फाउंडेशन द्वारा हेस्टर अफ्रीका को दिए गए सॉफ्ट लोन के संशोधन से होने वाला एक असाधारण लेखांकन लाभ शामिल है, जहाँ ऋण को USD 12 मिलियन से घटाकर USD 5 मिलियन कर दिया गया, संचित ब्याज माफ कर दिया गया, और संशोधित ऋण को ब्याज मुक्त कर दिया गया।
- प्रबंधन ने कहा कि पोल्ट्री हेल्थकेयर डिवीजन में पिछले वर्ष की इसी तिमाही की तुलना में 48% की वृद्धि हुई, जिसे उच्च संस्थागत कारोबार, गहरी बाजार पैठ, ग्राहक जुड़ाव और फीड सप्लीमेंट्स तथा कीटाणुनाशक समाधानों में शुरुआती ट्रैक्शन का समर्थन मिला।
- प्रबंधन ने कहा कि एनिमल हेल्थकेयर डिवीजन सरकार के नेतृत्व वाले टीकाकरण कार्यक्रमों, जैसे PPR उन्मूलन और गोट पॉक्स आपूर्ति के लिए लम्पी स्किन डिजीज कंट्रोल पहल, के समय से प्रभावित हुआ, जिसे वे अंतर्निहित मांग की समस्या के बजाय समय से संबंधित मुद्दा मानते हैं।
- प्रबंधन ने कहा कि जैविक पाइपलाइन का विस्तार करने के लिए तिमाही के दौरान पशु स्वास्थ्य खंड में नियामक डोजियर जमा किए गए, और 30 जून तक समेकित ऋण Rs. 103 crores था।
- મેનેજમેન્ટે જણાવ્યું કે સ્ટેન્ડઅલોન ધોરણે, ગયા વર્ષના સમાન ક્વાર્ટરની સરખામણીમાં ઓપરેશનમાંથી આવક 14% વધી અને PAT 88% વધ્યો, જ્યારે અનુકૂળ પ્રોડક્ટ મિક્સ અને ઓપરેશનલ કાર્યક્ષમતાના કારણે ગ્રોસ માર્જિન 69% થી સુધરીને 78% થયું, અને EBITDA 95% વધ્યો.
- મેનેજમેન્ટે જણાવ્યું કે કન્સોલિડેટેડ સ્તરે, નેપાળ અને આફ્રિકાના ઓપરેશન્સમાંથી નીચી આવકને કારણે ઓપરેશનમાંથી આવકમાં 8% નો ઘટાડો થયો, અને કન્સોલિડેટેડ નફાકારકતામાં ગેટ્સ ફાઉન્ડેશન દ્વારા હેસ્ટર આફ્રિકાને આપવામાં આવેલી સોફ્ટ લોનના સંશોધનથી થયેલો એક અસાધારણ એકાઉન્ટિંગ નફો સામેલ છે, જ્યાં લોનને USD 12 મિલિયનથી ઘટાડીને USD 5 મિલિયન કરવામાં આવી, વ્યાજ માફ કરવામાં આવ્યું, અને સંશોધિત લોનને વ્યાજમુક્ત બનાવવામાં આવી.
- મેનેજમેન્ટે જણાવ્યું કે પોલ્ટ્રી હેલ્થકેર ડિવીઝનમાં ગયા વર્ષના સમાન ક્વાર્ટરની સરખામણીમાં 48% ની વૃદ્ધિ થઈ, જેને ઉચ્ચ સંસ્થાગત વ્યવસાય, બજારમાં ઊંડા પ્રવેશ, ગ્રાહક જોડાણ અને ફીડ સપ્લીમેન્ટ્સ તથા જંતુનાશક ઉકેલોમાં પ્રારંભિક ટ્રેક્શનનો ટેકો મળ્યો.
- મેનેજમેન્ટે જણાવ્યું કે એનિમલ હેલ્થકેર ડિવીઝન સરકારની આગેવાની હેઠળના રસીકરણ પ્રોગ્રામ્સ, જેમ કે PPR નાબૂદી અને ગોટ પોક્સ પુરવઠા માટે લમ્પી સ્કિન ડિસીઝ કંટ્રોલ પહેલ, ના સમયથી પ્રભાવિત થયું, જેને તેઓ મૂળ માંગની સમસ્યાને બદલે સમય સંબંધિત મુદ્દો માને છે.
- મેનેજમેન્ટે જણાવ્યું કે બાયોલોજિકલ પાઇપલાઇનને વિસ્તૃત કરવા માટે ક્વાર્ટર દરમિયાન પશુ આરોગ્ય સેગમેન્ટમાં નિયમનકારી ડોઝિયર્સ સબમિટ કરવામાં આવ્યા, અને 30 જૂન સુધીમાં કન્સોલિડેટેડ દેવું Rs. 103 crores હતું.
What management said on the call, summarised by AI from the official transcript and checked against it. Read the transcript. Not a recommendation.
Smart-money activity
15/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 50.2% over the last 20 sessions vs 35.6% in the 40 before (1.41x); shares delivered per day 0.66x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Results
- 14 Jul 26Dividend Dividend ₹11 (ex-date) -5.2% next session
- 12 Nov 25Results Q2 FY26 results: net profit ₹14.4 cr +4.1% next session
- 6 Aug 25Dividend Dividend ₹7 (ex-date) -0.7% next session
- 30 Jan 25Results Q3 FY25 results: profit +193.0% YoY -6.6% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2025 | ₹71 cr | ₹14 cr | — | 16.5% | 16.85 |
| Dec 2024 | ₹63 cr | ₹12 cr | +193.0% | 8.0% | 13.41 |
| Jun 2024 | ₹82 cr | ₹6 cr | +8.0% | 21.5% | 8.8 |
| Mar 2024 | ₹79 cr | ₹5 cr | — | 20.1% | 7.52 |
Shareholding trend
| Holder | Jun 2026 | Mar 2026 | Sept 2025 |
|---|---|---|---|
| Promoters | 53.73% | 53.73% | 53.73% |
| Foreign institutions (FII) | 0.31% | 0.38% | 0.53% |
| Domestic institutions (DII) | 0.00% | 0.00% | 0.00% |
| Mutual funds | 0.00% | 0.00% | 0.00% |
| Retail investors | 18.42% | 18.76% | 18.35% |
| Number of shareholders | 11,961 | 12,373 | 12,260 |
Common questions
What was Hester Biosciences Limited's latest quarterly profit?
Hester Biosciences Limited reported a net profit of ₹14 cr for the quarter ended Sept 2025, on revenue of ₹71 cr.
How much do promoters hold in Hester Biosciences Limited?
Promoters held 53.73% of Hester Biosciences Limited at the end of Jun 2026, with 0.00% of promoter shares pledged.
Is Hester Biosciences Limited debt-free?
Its latest reported debt-to-equity ratio is 0.54.
What is Hester Biosciences Limited's P/E ratio?
About 14.3, based on the last 12 months' earnings and a price of ₹2,289.3 (data 2026-10-31).
What is the 52-week high and low of Hester Biosciences Limited?
The 52-week high is ₹2,683.6 and the 52-week low is ₹1,239.3.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Hester Biosciences Limited | ₹2,289.3 | ₹1,956 cr | 14.3 | — | 16.5% | 13% | 0.54 | +40.7% |
| Sakar Healthcare Ltd | ₹944.8 | ₹2,074 cr | 49 | 6.1 | 10% | 12.4% | 0.17 | +167.0% |
| Beta Drugs Ltd. | ₹1,798.4 | ₹2,000 cr | 36.9 | 4.6 | 18.8% | 16.6% | 0.62 | -4.8% |
| Indoco Remedies Limited | ₹208.3 | ₹1,923 cr | 60.1 | 1.9 | -9.7% | -2% | 1.15 | -25.0% |
| Panacea Biotec Limited | ₹313.25 | ₹1,917 cr | — | — | -0.6% | -6.3% | 0.03 | -29.8% |
| Windlas Biotech Ltd. | ₹876.1 | ₹1,810 cr | 28 | — | 12.2% | 13.5% | 0.06 | -8.4% |
Compare HESTERBIO with SAKAR in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open HESTERBIO in NSE Scanner →